Narcolepsy is a chronic neurological disorder, which is characterized by brain’s inability to control the sleep-wake cycle of an individual. This disorder is not caused due to any mental illness, but is mainly caused due to genetic abnormalities occurring from environmental factors or biologic factors. Narcoleptic individuals exhibita typical characteristic symptom, i.e. excessive daytime sleepiness (EDS), where individuals experience disturbed night sleep and abnormal daytime sleep pattern. Narcolepsy disorder is often confused with insomnia. Other major symptoms of this disorder include, cataplexy, sleep paralysis, hypnagogic hallucinations, automatic behavior and night weakness.

Browse Full Report: http://www.transparencymarketresearch.com/narcolepsy-market.html

Some of the major factors driving the growth of this market include increasing prevalence of various sleep disorders including narcolepsy, rising awareness about the disorder and increasing demand for advanced therapeutics and diagnostics.Narcoleptic disorder is equally prevalent to Parkinson’s disease or multiple sclerosis and is more prevalent than cystic fibrosis. There are more than 3 million people suffering from this disorder worldwide.Rising awareness about the disorder, and the resultant increase in demand for new and innovative drugs and other treatment optionswill lead to the growth of this market in future.

Geographically, North America dominates the global narcolepsy market followed by Europe. Major factors responsible for their dominance are high prevalence rate of narcolepsy in these regions. U.S. alone accounts for more than 200,000 narcoleptic individuals and is also characterized by high awareness levels among the general population. Asia-Pacific region exhibited fastest growth in this market due to increasing awareness levels about the disease and its treatment options and increasing spending power of the population.

Some of the key players operating in this market are Addrenex Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., BIOPROJET, Cephalon, Inc., Evotec AG, Graymark Healthcare, Inc., Hypnion, Inc., Jazz Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

North America
Asia Pacific
Europe
Rest of the World

This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Request For Report Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2362

About Us:-
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-
Mr.Sudip.S
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email:sales@transparencymarketresearch.com

Back to home page